Bispecific antibody therapeutic - Invenra/University of Wisconsin
Latest Information Update: 28 Feb 2023
At a glance
- Originator Invenra; University of Wisconsin-Madison
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuroblastoma
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Neuroblastoma in USA (Parenteral)
- 31 Jan 2019 Invenra and Wisconsin Alumni Research Foundation (WARF) enter into a collaboration for the development of a bispecific antibody therapeutic for Neuroblastoma
- 31 Jan 2019 Early research in Neuroblastoma in USA (Parenteral)